Abstract: A system and method for determining parameters of stimulation electrical signals for vagus nerve stimulation is discussed. Initial parameters of the signals are selected to provide reliable response to stimulation in physiological measurements of a subject. One or more physiological and neurological indices are determined based on a vagus nerve response model. For a selected vagus nerve activation, the electrical parameters of the signals are varied while monitoring changes in physiological parameters and values of the indices. The electrical parameters are varied until desired response in the physiological measurements and the values of the indices is observed. The electrical parameters are then stored as preferred parameters and can be used to activate the selected vagus nerve of the subject.

Abstract: A fastener includes an elongate fastener body defining a longitudinal axis substantially central thereto. The fastener body has a continuous outer fastener shell laterally surrounding the longitudinal axis. The fastener shell longitudinally separates a fastener head end and a fastener tip end. A tool-engaging feature is provided on the fastener head end. A plurality of teeth are located on the fastener shell and extend substantially laterally outward from the longitudinally axis. The fastener shell is comprised of at least one undulate face and at least one substantially flat face. The plurality of teeth are located only on the undulate faces. Each tooth is longitudinally separated from adjacent teeth along an undulate face. A method of installing the fastener into a receiving structure is also described.

Abstract: The present invention is related to the use of HMGB1 antagonists such as K883 in the treatment and/or prevention and/or inhibition of severe sepsis in mammals, e.g., humans, and pharmaceutical compositions for the same comprising HMGB1 antagonists in an effective amount to treat and/or prevent and/or inhibit this condition.

Abstract: A method performed by a first microservice processor includes receiving a first user indication from a first computing device from a plurality of computing devices of a second user that indicates that a first user requested a service of the second user. A first user-specific data container object is generated that includes first user-specific data elements associated with the service provided to the first user. First user-specific service-necessity information data objects are obtained from electronic resources. The first user-specific data elements and the first user-specific service-necessity information data objects are inputted into a machine learning engine to obtain ranked reference-claim data objects. A chosen reference-claim data object from the ranked reference-claim data objects is chosen by the second user to justify providing the service to the first user.

Abstract: The present disclosure relates to systems, methods and devices to monitor, diagnose and/or treat diseases or disorders comprising a calibration phase and a real-time diagnostic, treatment or monitoring phase, the calibration phase correlating a plurality of nerve activity measurements from a chronically implanted electrode in a subject with a plurality of concurrent measurements of levels of cytokines and/or glucose in the blood to obtain a functional relationship between blood cytokine and/or glucose levels and vagus nerve activity, and the diagnostic, treatment or monitoring phase analyzing the subject's real-time vagus nerve activity in accordance with the previously obtained functional relationship to initiate a treatment method.

Abstract: Methods and systems are described for detecting the likelihood of patent ductus arteriosus (PDA) in an infant using electrocardiogram and photoplethysmographic pulse signals obtained from the upper body and foot of the infant.

Abstract: Disclosed are apparatuses and methods for reducing or limiting blood loss and reducing bleed time in a subject by combined vagus and trigeminal stimulation. The apparatuses and methods may activate (e.g., electrically) one or more branches of the trigeminal nerve and may concurrently (at overlapping or near-overlapping time) independently activate the vagus nerve. This activation may be invasive or non-invasive.

Abstract: Methods for electrical modulation of inflammation or serum TNF levels in a subject.

Abstract: Disclosed are nerve stimulation assemblies adapted to apply stimulation signals to a person's nervous system. The assemblies are adapted to apply such signals to nerves terminating on the outer ear of a person, for example, the auricular branch of the vagus nerve. The assemblies comprise an ear canal extension adapted to fit within an ear canal of the person, a housing connected with the extension, and an electrode arm connected with the housing by a connection member. The connection member is adapted to articulate the electrode arm to position the electrode arm relative to the outer ear. An electrode is connected with a distal end of the arm. When the arm is articulated to a selected orientation and the extension is fitted in the ear canal, the electrode is in electrical contact with a portion of the outer ear innervated by a selected peripheral nerve, such as the vagus nerve.

Abstract: Methods are disclosed for treating ovarian tumors and ovarian and pancreatic cancers using computed and normalized relative ratios of plasma levels of phospholipids, particularly lysophosphatidylcholine, lysophosphatidylethanolamine, phosphatidylcholine, phosphatidylethanolamine and sphingomyelin.

Abstract: Methods are disclosed for treating ovarian tumors and ovarian and pancreatic cancers using computed and normalized relative ratios of plasma levels of phospholipids, particularly lysophosphatidylcholine, lysophosphatidylethanolamine, phosphatidylcholine, phosphatidylethanolamine and sphingomyelin.

Abstract: The present invention is related to the use of HMGB1 antagonists in the treatment and/or prevention and/or inhibition of acute lung injury in mammals, e.g., humans, and pharmaceutical compositions for the same comprising HMGB1 antagonists, in particular K883, in an effective amount to treat and/or prevent and/or inhibit this condition.

Abstract: Disclosed are apparatuses and methods for reducing or limiting bleeding (e.g., blood loss and/or bleeding time) in an animal by trigeminal stimulation. The apparatuses and methods may activate one or more branches of the trigeminal nerve. This activation may be invasive or non-invasive.

Abstract: Methods and systems are described for detecting the likelihood of patent ductus arteriosus (PDA) in an infant using electrocardiogram and photoplethysmographic pulse signals obtained from the upper body and foot of the infant.

Abstract: The present invention is related to the use of HMGB1 antagonists such as K883 in the treatment and/or prevention and/or inhibition of severe sepsis in mammals, e.g., humans, and pharmaceutical compositions for the same comprising HMGB1 antagonists in an effective amount to treat and/or prevent and/or inhibit this condition.

Abstract: Methods are disclosed for treating a subject having a disease or disorder comprising stimulating a nerve of the subject with a corrective stimulus pattern derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.

Abstract: Methods of treating HMGB1-mediated inflammation by administering a therapeutically effective amount of an MD2-antagonist to a subject in need thereof are described. The novel MD2 antagonist tetrapeptide P5779 is also described.

Abstract: Thioesters, thiocarbamates, thiocarbazates, semithiocarbazates, peptides, aza-amino acid conjugates, and azapeptides; and a chemoselective and site-specific functionalization protocol of protected thiocarbazates and semithiocarbazates are described. The protocol features the use of Mitsunobu reaction to alkylate specifically the nitrogen atom close to the acylthiol moiety with alcohols to produce protected mono-substituted thiocarbazates that can be stored for months, activated under mild conditions at low temperature using halonium reagents and integrated orthogonally to make substituted semicarbazides that can be used, e.g., as synthons in synthesis of aza-amino acid conjugates, azapeptides and other peptidomimetics.

Abstract: Apparatuses and methods for reducing or limiting bleeding in an animal by focused ultrasound (FUS) stimulation of the spleen. The apparatuses and methods may be used treat blood disorders such as hemophilia, or to reduce hemorrhage in surgery or due to traumatic injury. The methods may be non-invasively administered to the patient by transcutaneous application of ultrasound energy.

Abstract: Methods are disclosed for treating a subject having a disease or disorder comprising stimulating a nerve of the subject with a corrective stimulus pattern derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.